YMN-136 Vaccine
Phase 1Vaccine
YMN-136 Vaccine is one of 100 biologic programs targeting Liver Cancer. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
99
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
268 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Stivarga
BayerPhase 3
Adrucil
EElorac, Inc.
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Acetylsalicylic Acid
BayerPhase 3
Trifluridine/tipiracil
AbbViePhase 3
Telisotuzumab Adizutecan
AbbViePhase 3
XL092
RochePhase 3
TAS 102
Taiho Oncology, Inc.Phase 3
5-Fu
TToray Industries, Inc
Phase 3
PD-1 Monoclonal Antibody
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YMN-136 Vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Phase 1[1]
- Company
- WWest China Hospital